膽汁淤積性肝病具有臨床發(fā)病率高、病因復雜、發(fā)病機制不明確的特點。目前，有關膽汁淤積性肝病的有效治療藥物相對匱乏，中醫(yī)藥治療膽汁淤積肝損傷（CLI）療效及其作用機制研究備受關注。常用中藥包括清熱利濕類、活血化瘀類或涼血化痰類單味藥及相關復方，其改善CLI的作用機制研究多聚焦在法尼醇X受體（FXR）、組成型雄甾烷受體（CAR）、早期生長因子-1（EGR-1）、核因子E2相關因子（Nrf-2）等通路。結合當前國內外研究現(xiàn)狀，系統(tǒng)地闡述常見中藥單味藥和復方治療CLI的藥理作用機制，旨在為中藥治療CLI的臨床應用提供依據(jù)，為中藥創(chuàng)新藥開發(fā)及其深入研究提供參考。

Cholestatic liver disease has the characteristics of high clinical incidence, complex etiology and unclear pathogenesis. At present, there are relatively few effective drugs for the treatment of cholestatic liver disease. Therefore, the research on the efficacy and mechanism of traditional Chinese medicine in the treatment of cholestatic liver injury (CLI) has attracted much attention. The commonly used traditional Chinese medicines include single herbs of clearing heat and removing dampness, promoting blood circulation and removing blood stasis, or cooling blood and resolving phlegm and their related compounds. Research on the mechanism of action of traditional Chinese medicine in improving CLI focuses on the signaling pathways including farnesoid X receptor (FXR), constitutive androstane receptor (CAR), early growth factor-1 (EGR-1), and nuclear factor E2-related factor 2 (Nrf- 2). By combining with the current research status at home and abroad, this paper will focus on the prevention and treatment of CLI with traditional Chinese medicine, and systematically describe the mechanism of action of common traditional Chinese medicine single herbs and compound prescriptions in the treatment of cholestasis. The significance of this review is to provide a basis for the clinical application of traditional Chinese medicine in the treatment of CLI, and further provide a reference for the development of innovative traditional Chinese medicine and its in-depth research.

R287.5

天津市自然科學基金資助項目（18JCQNJC83800）；天津市教委科研計劃項目（2021KJ159，2021ZD030）；天津中醫(yī)藥大學第二附屬醫(yī)院“青苗計劃”項目（QMJH202007）